Fragile X SyndromeCRISPRプラスミド
サンタクルスバイオテクノロジー社は遺伝子サイレンシング用のCRISPR/Cas9ノックアウト及びCRISPR Double Nickaseプラスミドを含め、広範囲の遺伝子編集製品を提供しております。Fragile X Syndrome遺伝子サイレンサーは、Fragile X Syndrome CRISPR/Cas9ノックアウトプラスミドとFragile X SyndromeDouble Nickaseプラスミドとして利用可能です。遺伝子活性化用のFragile X SyndromeCRISPR/dCas9 Activationプラスミド及びCRISPR Lenti Activationシステムも利用できます。遺伝子サイレンサーと活性化剤はタンパク質の検出に使用された抗体と組み合わせた遺伝子研究に有用です。
Fragile X Syndrome CRISPR Knockout, HDR and Double Nickase Plasmids
| Empty Table Header | 製品名 | CATALOG # | Species | アプリケーション | MARKER | 引用文献 | レーティング |
|---|---|---|---|---|---|---|---|
FXR1 CRISPR/Cas9 KOプラスミド (h) | sc-402570 | h | Gene Knockout | GFP | 0 | ||
FXR1 HDRプラスミド (h) | sc-402570-HDR | h | Homology Directed Repair | Puromycin | 0 | ||
FXR1 Double Nickaseプラスミド (h) | sc-402570-NIC | h | Gene Knockout | Puromycin | 0 | ||
FXR1 Double Nickaseプラスミド (h2) | sc-402570-NIC-2 | h | Gene Knockout | Puromycin | 0 | ||
FXR1 CRISPR/Cas9 KOプラスミド (m) | sc-420430 | m | Gene Knockout | GFP | 0 | ||
FXR1 Double Nickaseプラスミド (m) | sc-420430-NIC | m | Gene Knockout | Puromycin | 0 | ||
FXR1 Double Nickaseプラスミド (m2) | sc-420430-NIC-2 | m | Gene Knockout | Puromycin | 0 | ||
FXR2 CRISPR/Cas9 KOプラスミド (h) | sc-406602 | h | Gene Knockout | GFP | 0 | ||
FXR2 HDRプラスミド (h) | sc-406602-HDR | h | Homology Directed Repair | Puromycin | 0 | ||
FXR2 Double Nickaseプラスミド (h) | sc-406602-NIC | h | Gene Knockout | Puromycin | 0 | ||
FXR2 Double Nickaseプラスミド (h2) | sc-406602-NIC-2 | h | Gene Knockout | Puromycin | 0 | ||
FXR2 CRISPR/Cas9 KOプラスミド (m) | sc-423876 | m | Gene Knockout | GFP | 0 | ||
FXR2 HDRプラスミド (m) | sc-423876-HDR | m | Homology Directed Repair | Puromycin | 0 | ||
FXR2 Double Nickaseプラスミド (m) | sc-423876-NIC | m | Gene Knockout | Puromycin | 0 | ||
FXR2 Double Nickaseプラスミド (m2) | sc-423876-NIC-2 | m | Gene Knockout | Puromycin | 0 |
Fragile X Syndrome CRISPR Activation Products
| Empty Table Header | 製品名 | CATALOG # | Species | アプリケーション | MARKER | 引用文献 | レーティング |
|---|---|---|---|---|---|---|---|
FXR1 CRISPR Activationプラスミド (h) | sc-402570-ACT | h | Gene Activation | Puro, Blast, Hygro | 0 | ||
FXR1 CRISPR Activationプラスミド (h2) | sc-402570-ACT-2 | h | Gene Activation | Puro, Blast, Hygro | 0 | ||
FXR1 Lentiviral Activation Particles (h) | sc-402570-LAC | h | Gene Activation | Puro, Blast, Hygro | 0 | ||
FXR1 Lentiviral Activation Particles (h2) | sc-402570-LAC-2 | h | Gene Activation | Puro, Blast, Hygro | 0 | ||
FXR1 CRISPR Activationプラスミド (m) | sc-420430-ACT | m | Gene Activation | Puro, Blast, Hygro | 0 | ||
FXR1 CRISPR Activationプラスミド (m2) | sc-420430-ACT-2 | m | Gene Activation | Puro, Blast, Hygro | 0 | ||
FXR1 Lentiviral Activation Particles (m) | sc-420430-LAC | m | Gene Activation | Puro, Blast, Hygro | 0 | ||
FXR1 Lentiviral Activation Particles (m2) | sc-420430-LAC-2 | m | Gene Activation | Puro, Blast, Hygro | 0 | ||
FXR2 CRISPR Activationプラスミド (h) | sc-406602-ACT | h | Gene Activation | Puro, Blast, Hygro | 0 | ||
FXR2 CRISPR Activationプラスミド (h2) | sc-406602-ACT-2 | h | Gene Activation | Puro, Blast, Hygro | 0 | ||
FXR2 Lentiviral Activation Particles (h) | sc-406602-LAC | h | Gene Activation | Puro, Blast, Hygro | 0 | ||
FXR2 Lentiviral Activation Particles (h2) | sc-406602-LAC-2 | h | Gene Activation | Puro, Blast, Hygro | 0 | ||
FXR2 CRISPR Activationプラスミド (m) | sc-423876-ACT | m | Gene Activation | Puro, Blast, Hygro | 0 | ||
FXR2 CRISPR Activationプラスミド (m2) | sc-423876-ACT-2 | m | Gene Activation | Puro, Blast, Hygro | 0 | ||
FXR2 Lentiviral Activation Particles (m) | sc-423876-LAC | m | Gene Activation | Puro, Blast, Hygro | 0 | ||
FXR2 Lentiviral Activation Particles (m2) | sc-423876-LAC-2 | m | Gene Activation | Puro, Blast, Hygro | 0 |